AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Wednesday 18 November 2026
News from the 24 hours to Wednesday morning, 18 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mostly positive, centred on new US and EU approvals including Klygefa, a dismissed antitrust lawsuit and a Jefferies price target increase. The Indian arm's tie-up with Strand Life Sciences added mild support, while a layoff-related law firm probe and a small share dip were minor negatives.
What drove it
- regulatory approvals
- Soliris lawsuit dismissed
- Indian unit partnership
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Thu 12 Nov | +7.5 | 25 |
| Fri 13 Nov | +5.3 | 8 |
| Sat 14 Nov | +5.5 | 39 |
| Sun 15 Nov | +7.5 | 9 |
| Mon 16 Nov | +4.5 | 6 |
| Tue 17 Nov | +9.7 | 45 |
| Wed 18 Nov | +7.0 | 29 |
15 stories · 29 headlines · strongest first
Pharma and healthcare on 18 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Strand Life Sciences and AstraZeneca Pharma India sign letter of intent +3.610 headlines today · Many outlets report that Strand Life Sciences, a Reliance unit, and AstraZeneca Pharma India signed a letter of intent. | ||
| +5.8 | Indian shares gain after partnership announcement. | |
| +3.3 | Indian arm signs letter of intent with Reliance unit. | |
| +3.3 | Indian unit agrees to explore healthcare collaboration. | |
| +3.3 | Indian arm signs preliminary collaboration deal. | |
| +3.3 | Indian unit signs collaboration letter of intent. | |
| +3.3 | Indian arm partners on healthcare collaboration. | |
| +3.3 | Indian arm teams up with Reliance-owned genomics firm. | |
| +3.3 | Indian arm signs letter of intent with Reliance unit. | |
| +3.3 | Indian subsidiary explores healthcare collaboration with a partner. | |
| +3.3 | Indian unit signs preliminary letter of intent for collaboration. | |
| AstraZeneca wins several regulatory approvals +9.33 headlines today · 8 in all, since 17 November · Articles describe approvals AstraZeneca received for cardiovascular, cancer and rare disease treatments. | ||
| +10.0 | Multiple approvals across several therapy areas. | |
| +8.3 | New US and EU approvals secured during the week. | |
| +7.5 | Two regulatory approvals in one day, with evidence comparison. | |
| AstraZeneca's Klygefa approved for myasthenia gravis in US and EU +10.02 headlines today · 19 in all, since 15 November · Reports say Klygefa, a medicine for myasthenia gravis that patients inject themselves once a week, has been approved by the FDA and in the EU. | ||
| +10.0 | US regulator clears new weekly self-injected rare disease drug. | |
| +9.2 | Approvals in US and EU for new drug; gains in focus. | |
| AstraZeneca unit defeats Soliris monopolisation suit +8.32 headlines today · 4 in all, since 17 November · Reports say AstraZeneca's unit won dismissal of the Soliris antitrust lawsuit. | ||
| +8.3 | Antitrust lawsuit over biosimilar delays thrown out in its favour. | |
| +8.3 | Court dismisses antitrust claim against the company. | |
| AstraZeneca pipeline and market commentary +5.82 headlines today · Commentary pieces discuss AstraZeneca's pipeline momentum and setup. | ||
| +6.7 | Positive take on its developing drug pipeline. | |
| +5.0 | Generally favourable commentary on the share setup. | |
| Jefferies raises AstraZeneca target, keeps Buy +9.21 headline today · Jefferies lifted its AstraZeneca price target and maintained a Buy rating. | ||
| +9.2 | Broker keeps buy view and lifts price target. | |
| FDA approves Imfinzi regimen for bladder cancer +10.01 headline today · 15 in all, since 14 November · The FDA has approved the regimen from AstraZeneca's VOLGA trial to treat muscle-invasive bladder cancer. | ||
| +9.2 | Regulatory clearance for bladder cancer treatment regimen. | |
| AstraZeneca shares have risen 12% over the past month +6.71 headline today · An article considers whether investors should purchase, dispose of or keep AstraZeneca shares after they rose 12% over a month. | ||
| +6.7 | Shares have risen strongly over the past month. | |
| AstraZeneca reduces its US sales workforce by 600 positions −3.01 headline today · 21 in all, since 14 November · A law firm announced a WARN Act investigation concerning AstraZeneca. | ||
| −6.7 | Law firm probing possible mass layoff notice issues. | |
| AstraZeneca has acquired Omniose +5.01 headline today · A biotech round-up reports AstraZeneca acquired Omniose. | ||
| +5.0 | Acquisition of a biotech firm mentioned among sector news. | |
| AstraZeneca marks Macclesfield campus 60th anniversary +4.21 headline today · AstraZeneca celebrated 60 years of its Macclesfield campus with a Guinness World Record attempt. | ||
| +4.2 | Positive site anniversary celebration with record attempt. | |
| AstraZeneca signs cloud ERP deal with SAP +2.91 headline today · 6 in all, since 15 November · SAP Cloud ERP Private is reported to be the platform AstraZeneca is migrating to. | ||
| +1.7 | Internal IT systems upgrade; minor operational story. | |
| AstraZeneca explains HER2 biomarker +1.71 headline today · AstraZeneca published an explainer on the HER2 biomarker. | ||
| +1.7 | Company-published educational piece on cancer biomarker. | |
| AstraZeneca shares trade below Xetra close −1.71 headline today · A report notes AstraZeneca shares trading below their Xetra close. | ||
| −1.7 | Small share price dip versus prior German close. | |
| AstraZeneca Pharma India asks shareholders to approve a new independent director 0.01 headline today · AstraZeneca Pharma India is seeking shareholder approval for a new independent director. | ||
| 0.0 | Routine governance matter at Indian subsidiary. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.